The new weight loss pill developed by Novo Nordisk, called amycretin, has shown promising results in early trials, with patients losing 13% of their body weight in 12 weeks, compared to 6% with the existing jab Wegovy.
Amycretin mimics hormones that regulate appetite and seems more potent due to its additional hormone mimicry.
Novo Nordisk’s shares surged after these results, making it Europe’s most valuable listed company.
The pill’s potential success could offer a more convenient alternative to injections for weight loss treatment.
While further research is needed to confirm its long-term effectiveness and safety, the initial findings have sparked optimism among investors and the pharmaceutical industry.
Dive deeper: Click here to explore more of the latest news stories and viral videos
Discover more from Your Assignment Editor
Subscribe to get the latest posts sent to your email.
